Clinical trial
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in…
NCT04292899 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT04292899 |
|---|---|
| Title | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) |
| Official title | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | Remdesivir, Standard of Care |
| Enrollment | 4,891 |
| Start date | Mar 6, 2020 |
| Primary completion | Apr 9, 2020 |
| Completion | Jun 30, 2020 |
| First posted | Mar 3, 2020 |
| Last update posted | Dec 31, 2020 |
| Countries | China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: